Issue navigation
Volume 112, Issue 4, April 2020
Editorials
Stomaching Multigene Panel Testing: What to Do About CDH1?
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 325–326, https://doi.org/10.1093/jnci/djz230
Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the “Undruggable”
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 327–329, https://doi.org/10.1093/jnci/djz156
Commentary
CDH1 on Multigene Panel Testing: Look Before You Leap
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 330–334, https://doi.org/10.1093/jnci/djz229
Review
A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 335–342, https://doi.org/10.1093/jnci/djz211
Articles
Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 343–355, https://doi.org/10.1093/jnci/djz155
The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 356–368, https://doi.org/10.1093/jnci/djz134
Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 369–376, https://doi.org/10.1093/jnci/djz124
The Association of Abdominal Adiposity With Mortality in Patients With Stage I–III Colorectal Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 377–383, https://doi.org/10.1093/jnci/djz150
Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 384–390, https://doi.org/10.1093/jnci/djz127
Mammographic Density Change and Risk of Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 391–399, https://doi.org/10.1093/jnci/djz149
Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 400–409, https://doi.org/10.1093/jnci/djz131
Racial Comparisons in Timeliness of Colon Cancer Treatment in an Equal-Access Health System
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 410–417, https://doi.org/10.1093/jnci/djz135
Brief Communication
Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 418–422, https://doi.org/10.1093/jnci/djz194
Correspondence
RE: Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 423–424, https://doi.org/10.1093/jnci/djz138
Response to Tomao, Panici, and Tomao
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Page 425, https://doi.org/10.1093/jnci/djz140
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Pages 426–427, https://doi.org/10.1093/jnci/djz162
Response to Yang, Shi, Wang et al.
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 4, April 2020, Page 428, https://doi.org/10.1093/jnci/djz163
